ImmunityBio Faces Securities Fraud Suit Over Anktiva Cancer Claims

ImmunityBio, Inc. ($IBRX) is now the subject of an active securities fraud class action lawsuit following regulatory action that exposed allegedly false and misleading statements about the company's flagship immunotherapy candidate. The lawsuit centers on claims made by company executives about Anktiva, the biotech firm's lead product, which the FDA determined were inaccurate and unsubstantiated. With the stock having collapsed nearly one-quarter of its value in the wake of the regulator's warning, investors who purchased securities during a specific window face a May 26, 2026, deadline to seek lead plaintiff status in the litigation.

The Regulatory Trigger and Stock Collapse

On March 24, 2026, the FDA issued a Warning Letter to ImmunityBio directly addressing statements made by company executives. According to the regulatory action, executives had made inaccurate claims that Anktiva could "cure and even prevent all cancer"—assertions that the FDA determined were false and misleading.

The market's response was swift and severe. Following the FDA's public warning letter, IBRX stock experienced a dramatic selloff, declining 21.12% to close at $7.42 per share. This sharp decline reflects investor concern about the company's credibility, the viability of its lead candidate, and the potential for litigation exposure stemming from the alleged misrepresentations.

The securities fraud class action was subsequently filed by Kessler Topaz Meltzer & Check, LLP, one of the nation's prominent securities litigation firms. The lawsuit targets the period during which investors allege the company made these false statements without disclosure of the regulatory issues that would eventually trigger the FDA warning letter.

Key Timeline and Legal Framework

Investors seeking to participate in the class action have until May 26, 2026, to file a motion for lead plaintiff status. This deadline is critical for investors who purchased or otherwise acquired ImmunityBio securities between January 19 and March 24, 2026—the period during which the alleged misrepresentations were made and before public disclosure of the FDA warning.

The lead plaintiff role is important in securities class actions, as the designated lead plaintiff works closely with counsel to represent all class members and has significant input on litigation strategy. Investors with substantial losses typically have priority in being selected as lead plaintiffs.

Market Context: Biotech's Credibility Challenge

This case highlights a persistent tension in the biotechnology sector between the need to communicate promising research developments to investors and the requirement to make only truthful, substantiated claims about drug efficacy. The immunotherapy space, particularly in oncology, has seen intense investor interest as companies race to develop breakthrough treatments.

ImmunityBio's public statements about Anktiva's potential appear to have crossed the line from aspirational to false in the eyes of regulators. Claims that a drug could "cure and even prevent all cancer" would require extraordinary clinical evidence, which—if such evidence existed—would typically already be disclosed and discussed in detail. The FDA's intervention suggests that no such evidence supported these broad assertions.

The incident carries broader implications for the biotech sector:

• Regulatory scrutiny: Companies face increased FDA oversight of marketing claims and public statements about investigational drugs
• Investor skepticism: Incidents like this may make institutional investors more cautious about biotech companies' communications
• Legal liability: Securities fraud litigation creates significant financial and reputational costs beyond regulatory penalties
• Clinical trial transparency: The case underscores the importance of distinguishing between preclinical data, early-stage trial results, and definitive clinical evidence

Investor Implications and Class Action Mechanics

For shareholders who purchased IBRX between January 19 and March 24, 2026, this class action represents a potential avenue to recover losses stemming from the 21.12% stock decline following the FDA warning. The securities litigation system allows investors harmed by corporate misstatements to seek damages from the company and potentially its officers and directors.

The May 26, 2026 deadline is absolute—missing this date typically forecloses investors' ability to pursue lead plaintiff status and can affect their participation in the case overall. Investors with significant holdings during this period should consult with securities counsel to understand their options and potential recovery mechanisms.

Beyond individual recovery, this lawsuit serves as a cautionary tale for the broader biotech community. Public company executives must ensure that all statements about drug potential are supported by actual clinical data and must carefully distinguish between investigational compounds and approved therapies. The FDA's willingness to issue a warning letter and the subsequent securities litigation create a powerful incentive structure for accurate disclosure.

The case also raises questions about ImmunityBio's clinical development program for Anktiva. If the company made such broad claims, what was the actual status of the drug's clinical trials? Understanding the gap between public claims and clinical reality will be critical for any recovery estimate in this litigation.

Looking Forward

As the May 26, 2026 deadline approaches, investors who purchased ImmunityBio securities during the alleged misrepresentation period should act quickly to determine their eligibility and potential recovery. The Kessler Topaz Meltzer & Check class action represents one of the market's mechanisms for holding companies accountable when executives stray from truthful disclosure requirements.

For ImmunityBio more broadly, the company now faces a multi-front challenge: the FDA warning letter, the securities class action, the decimated stock price, and the task of rebuilding investor confidence in its scientific claims and regulatory compliance. The 21.12% stock decline reflects not just the immediate impact of the warning letter, but market concern about the company's future viability and its ability to successfully develop and commercialize Anktiva if the clinical evidence doesn't support its claims.